These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
742 related articles for article (PubMed ID: 16713013)
21. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195 [TBL] [Abstract][Full Text] [Related]
22. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. Edelman MJ; Chansky K; Gaspar LE; Leigh B; Weiss GR; Taylor SA; Crowley J; Livingston R; Gandara DR J Clin Oncol; 2004 Jan; 22(1):127-32. PubMed ID: 14701775 [TBL] [Abstract][Full Text] [Related]
23. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149 [TBL] [Abstract][Full Text] [Related]
24. Paclitaxel, carboplatin, and oral etoposide: a phase II trial in limited-stage small cell lung cancer. Gatzemeier U; Jagos U; Kaukel E; Koschel G; von Pawel J Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-149-S12-152. PubMed ID: 9331141 [TBL] [Abstract][Full Text] [Related]
25. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Neill HB; Miller AA; Clamon GH; Perry MC; Crawford J; Green MR Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-130-S12-134. PubMed ID: 9331137 [TBL] [Abstract][Full Text] [Related]
26. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659 [TBL] [Abstract][Full Text] [Related]
27. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Hainsworth JD; Burris HA; Greco FA Semin Oncol; 2001 Apr; 28(2 Suppl 4):43-7. PubMed ID: 11479897 [TBL] [Abstract][Full Text] [Related]
28. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study. Dimitroulis J; Rapti A; Stathopoulos GP; Rigatos S; Stathopoulos J; Koutantos J; Athanasiadis A; Tsikritsaki K; Karaindros D; Katis K; Antoniou D; Toumbis M; Giamboudakis P Oncol Rep; 2008 Oct; 20(4):879-84. PubMed ID: 18813830 [TBL] [Abstract][Full Text] [Related]
29. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Perez EA; Geoffroy FJ; Hillman S; Johnson EA; Farr GH; Tazelarr HD; Hatfield AK; Krook JE; Maillard JA; Levitt R; Marks RS Lung Cancer; 2004 Jun; 44(3):347-53. PubMed ID: 15140548 [TBL] [Abstract][Full Text] [Related]
30. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G; Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419 [TBL] [Abstract][Full Text] [Related]
31. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997 [TBL] [Abstract][Full Text] [Related]
32. Comparison of carboplatin/etoposide/vincristine with cisplatin/etoposide as combination chemotherapy for small cell lung cancer. Kumagai M; Kutsuzawa T; Fuyuno G; Kondo T; Shioya S; Ohta Y Tokai J Exp Clin Med; 1995 Dec; 20(4-6):209-14. PubMed ID: 8956462 [TBL] [Abstract][Full Text] [Related]
33. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308 [TBL] [Abstract][Full Text] [Related]
34. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR; J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656 [TBL] [Abstract][Full Text] [Related]
35. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. Hainsworth JD; Spigel DR; Litchy S; Greco FA J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720 [TBL] [Abstract][Full Text] [Related]
37. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153 [TBL] [Abstract][Full Text] [Related]
38. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ; J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432 [TBL] [Abstract][Full Text] [Related]
39. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869 [TBL] [Abstract][Full Text] [Related]
40. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]